Immunocore (IMCR) Revenue & Revenue Breakdown
Immunocore Revenue Highlights
Latest Revenue (Y)
$400.02M
Latest Revenue (Q)
$103.69M
Main Segment (Y)
Sale of Therapies
Main Geography (Y)
UNITED STATES
Immunocore Revenue by Period
Immunocore Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $400.02M | 61.45% |
| 2024-12-31 | $247.77M | -0.66% |
| 2023-12-31 | $249.43M | 72.93% |
| 2022-12-31 | $144.23M | 295.34% |
| 2021-12-31 | $36.48M | 21.15% |
| 2020-12-31 | $30.11M | 17.32% |
| 2019-12-31 | $25.67M | 8.52% |
| 2018-12-31 | $23.65M | - |
Immunocore generated $400.02M in revenue during NA 2025, up 61.45% compared to the previous quarter, and up 1328.34% compared to the same period a year ago.
Immunocore Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $103.69M | 5.85% |
| 2025-06-30 | $97.96M | 4.35% |
| 2025-03-31 | $93.88M | 11.69% |
| 2024-12-31 | $84.05M | 4.74% |
| 2024-09-30 | $80.25M | 6.43% |
| 2024-06-30 | $75.40M | 6.95% |
| 2024-03-31 | $70.50M | -0.38% |
| 2023-12-31 | $70.77M | 9.13% |
| 2023-09-30 | $64.85M | 7.22% |
| 2023-06-30 | $60.48M | 9.86% |
| 2023-03-31 | $55.06M | 14.55% |
| 2022-12-31 | $48.06M | 16.66% |
| 2022-09-30 | $41.20M | 28.74% |
| 2022-06-30 | $32.00M | 42.40% |
| 2022-03-31 | $22.47M | 240.88% |
| 2021-12-31 | $6.59M | 11.29% |
| 2021-09-30 | $5.92M | 3.33% |
| 2021-06-30 | $5.73M | -30.68% |
| 2021-03-31 | $8.27M | 11.46% |
| 2020-12-31 | $7.42M | 11.55% |
| 2020-09-30 | $6.65M | -14.58% |
| 2020-06-30 | $7.79M | -5.67% |
| 2020-03-31 | $8.26M | 46.31% |
| 2019-12-31 | $5.64M | - |
Immunocore generated $103.69M in revenue during Q3 2025, up 5.85% compared to the previous quarter, and up 137.52% compared to the same period a year ago.
Immunocore Revenue Breakdown
Immunocore Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Sale of Therapies | $400.02M | $309.99M | - | - | - |
| Collaboration Revenue | - | $213.00K | - | - | - |
| Product Revenue | - | - | $238.74M | - | - |
| Genentech | - | - | - | $2.48M | $17.43M |
| GlaxoSmithKline | - | - | - | - | $6.08M |
| Eli Lilly | - | - | - | - | - |
Immunocore's latest annual revenue breakdown by segment (product or service), as of Dec 25: Sale of Therapies (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 |
|---|---|---|---|---|---|---|---|
| Sale of Therapies | $104.48M | $103.69M | $97.96M | $93.88M | - | - | - |
| Collaboration Revenue | - | - | - | - | $53.00K | $160.00K | - |
| Product | - | - | - | - | - | $80.25M | - |
| Product Revenue | - | - | - | - | - | - | $70.34M |
Immunocore's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Sale of Therapies (100.00%).
Immunocore Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Rest of World | $11.60M | $3.60M | $871.00K | - | - |
| UNITED STATES | $257.00M | $226.69M | $169.79M | - | - |
| Europe | $131.42M | $73.22M | $67.63M | $35.49M | $3.01M |
| International | - | $10.08M | $3.60M | - | - |
| United States | - | - | - | $80.45M | $17.43M |
| UK | - | - | - | - | $6.08M |
Immunocore's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (64.25%), Europe (32.85%), and Rest of World (2.90%).
Quarterly Revenue by Country
| Country | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 |
|---|---|---|---|---|---|---|---|
| Europe | $32.05M | $33.53M | $33.04M | $32.80M | $33.17M | $21.10M | $18.95M |
| Rest of World | $3.42M | $2.87M | $835.00K | $1.36M | - | - | - |
| UNITED STATES | $69.00M | $67.30M | $64.09M | $56.61M | $119.39M | $57.27M | $50.03M |
| International | - | - | - | $4.47M | $8.20M | $1.88M | - |
Immunocore's latest quarterly revenue breakdown by geography, as of Dec 25: UNITED STATES (66.05%), Europe (30.68%), and Rest of World (3.28%).
Immunocore Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HRMY | Harmony Biosciences | $868.45M | $239.46M |
| IMCR | Immunocore | $400.02M | $103.69M |
| MNKD | MannKind | $348.97M | $82.13M |
| XERS | Xeris Biopharma | $291.85M | $71.54M |
| ABCL | AbCellera Biologics | $75.13M | $8.96M |
| NUVB | Nuvation Bio | $62.90M | $13.12M |
| JANX | Janux Therapeutics | $10.00M | $10.00M |
| CLDX | Celldex Therapeutics | $1.54M | - |
| SION | Sionna Therapeutics | - | - |
| VERA | Vera Therapeutics | - | - |
| BHVN | Biohaven | - | - |